Pfizer (PFE) is back in focus after the company said Chief Financial Officer Dave Denton will leave in August, with long-time finance executive Cecile Guegan stepping in as interim CFO during the search for a successor.

The CFO announcement comes as Pfizer shares trade at US$25.21, with the stock down over the past quarter but posting a 12.52% total shareholder return over the last year. This suggests that shorter term momentum has cooled even as income and dividend effects support longer term results.

If the leadership change has you reassessing your watchlist, it could be a good moment to look beyond big pharma and review 40 healthcare AI stocks as potential additions alongside Pfizer.

With Pfizer now trading at US$25.21 after a weaker recent quarter but a 12.52% total shareholder return over the past year, the key question is whether investors are overlooking value or whether markets already reflect its recovery story.

Most Popular Narrative: 10% Undervalued

With Pfizer closing at $25.21 against a narrative fair value of $28.00, the current price sits below what this widely followed view considers reasonable, setting up a clear tension between market pricing and long term expectations.

Em resumo, o futuro da PFE é uma história de transição: de gigante pandêmico para uma big pharma diversificada e inovadora. Os próximos anos serão de defesa contra o patent cliff, mas com sementes plantadas para um renascimento. Para investidores pacientes, a Pfizer oferece valor e rendimento; para os mais agressivos, o upside virá da execução impecável do pipeline. Em um setor farmacêutico em constante evolução, a Pfizer parece posicionada não para dominar como nos anos COVID, mas para sobreviver e prosperar, uma narrativa clássica de resiliência corporativa.

Curious what sits behind that transition story for Pfizer? The narrative leans on specific revenue paths, margin assumptions and a detailed view of how the patent cliff is absorbed. The pipeline, acquisition payoffs and future cash generation are all wired into that $28.00 figure. The full breakdown shows exactly how those moving parts connect.

Result: Fair Value of $28.00 (UNDERVALUED)

However, that transition story for Pfizer could be knocked off course if the patent cliff bites harder than expected or key pipeline assets face regulatory or clinical setbacks.

Next Steps

If this mix of risks and potential rewards around Pfizer leaves you unsure, take a closer look now and review the 1 key reward and 4 important warning signs in detail.

Looking for more investment ideas beyond Pfizer?

If the Pfizer story has sharpened your focus, now is the time to widen your search and line up a few more quality candidates on your radar.

• Target consistent income potential by reviewing 8 dividend fortresses that may help anchor your portfolio with steadier cash flows.
• Hunt for mispriced quality by scanning screener containing 19 high quality undiscovered gems that could be flying under the radar before broader attention arrives.
• Strengthen your defensive core by filtering for 66 resilient stocks with low risk scores that can help balance out more volatile positions.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.